Last reviewed · How we verify
NCT07435090
Efficacy and Safety of Rimegepant for Acute Dizziness
Phase 2, PHASE3 trial testing Rimegepant 75mg Orally Disintegrating Tablets (ODT) in Dizziness in 370 participants. Not yet recruiting.
31 December 2027
Quick facts
| Lead sponsor | Shi Tianming |
|---|---|
| Phase | Phase 2, PHASE3 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 370 |
| Start date | 20 March 2026 |
| Primary completion | 31 December 2027 |
| Estimated completion | 30 June 2028 |
Drugs / interventions tested
- Rimegepant 75mg Orally Disintegrating Tablets (ODT) (rimegepant-75mg-orally-disintegrating-tablets-odt) — full drug profile →
- Betahistine Mesylate tablet
Conditions studied
- Dizziness — all drugs for Dizziness →
Sponsor
Shi Tianming
Who can join
Adults 18 to 65, any sex, with Dizziness. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to explore the efficacy and safety of rimegepant for acute dizziness, including vestibular migraine (VM) and benign recurrent vertigo (BRV), through a multicenter, randomized controlled clinical trial. This study addresses the urgent clinical need for effective therapies for acute dizziness. Additionally, we will dynamically observe the changes in calcitonin gene-related peptide (CGRP) levels before and after treatment and explore the predictive value of CGRP levels for treatment efficacy and the prognosis of recurrence in patients. This study aims to provide a scientific basis to improve clinical management strategies for acute dizziness.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07435090
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Rimegepant 75mg Orally Disintegrating Tablets (ODT)
Trials testing the same drug.
- NCT05371652 — A Study to Learn About the Long-term Safety of Rimegepant for the Acute Treatment of Migraine in Chinese Participants · Phase 3 · completed
Other recruiting trials for Dizziness
Currently open trials in the same condition.
- NCT07225023 — A Multi-Site Feasibility Trial of Embedded Emergency Department Physical Therapy for Dizziness · NA · recruiting
- NCT06893029 — Dizziness Due to Visual Stimuli in Patients With Concussion and Other Causes of Dizziness: Examination of Balance Behavi · NA · recruiting
- NCT06704698 — Postoperative Analgesia Between Paravertebral Block and Epidural Block in Esophageal Surgery · NA · recruiting
- NCT06222450 — Vestibular Rehabilitation App for Adults With Dizziness Related to mTBI · NA · recruiting
- NCT07099222 — Efficacy of Non-weight Based, Low Dose Dex-Dex Adjuncts in Prolonging Peripheral Nerve Blocks · Phase 1, PHASE2 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07435090 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shi Tianming
- Last refreshed: 27 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07435090.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing